This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - 1200.181

Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)

Nobuyuki Yamamoto, Toshihiro Nukiwa, Yoichi Nakanishi, Akihiko Gemma, Masaya Mizushima, Tomoyuki Takayama, Jun Kumazawa, Hisaya Azuma, Kazuo Tamura

Yamamoto 1200.181 - WCLC 2017 Poster

Related Material

Learn more about the science behind this poster in the videos, papers and other materials below.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

Sequist LV, et al. J Clin Oncol 2013;31:3327–34

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Wu YL, et al. Lancet Oncol 2014;15:213–22

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang JC, et al. Lancet Oncol 2015;16:141–51

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3

Kato T, et al. Cancer Sci 2015;106:1202–11

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017
Back to top